The POC market report (NGAL included)

By On 14. December 2012 · Leave a Comment · In BioPorto

Instead of spending/wsting time christmas shopping – studying this little report might prove usefull. Market prognosis for the POC-market including the Triage NGAL-tet from Alere… I’d love to read it – but the pricetag of 994 $ seems a little to much 🙂

 

http://www.reportlinker.com/p01054644/Hospital-based-Point-of-Care-Diagnostics-Products-Players-and-Outlook-to.html

About Stengaard

BioPorto investor from way back when... I've invested in BioPorto ever since they made their debut on the danish stock exchange, it been a looooong journey with many obstacles. But well worth it all if Bioporto maintains their patent after the proceedings in 2014, and enters into agreements with Global Distributors in 2012 and 2013 If not, then it'll take another xx.years 🙂

Related posts:

  1. Will they ever bring the NGAL test to the market? In November 2010, a productmanager from Beckman Coulter Diagnostics said:...
  2. NGAL test Distribution Agreement with Wiener Group Today BioPorto announced that they have entered into a Distribution...
  3. A little ray of weekend (NGAL) sunshine Its pouring down here in the Lake district, but here’s...
  4. Revokation of CCH’s NGAL patent (Cincinnati Children’s Hospital) We have the greatest respect for the work of CCH,...
  5. The NGAL Test at Hvidovre Hospital Symposium about NGAL at Hvidovre Hospital, Copenhagen Senior Consultant and...
 

Leave a Reply

Your email address will not be published. Required fields are marked *

Set your Twitter account name in your settings to use the TwitterBar Section.